Shinozaki Katsunori, Nitta Tomoko, Yamauchi Masami, Doi Mihoko
Dept. of Clinical Oncology, Hiroshima Prefectural Hospital, Japan.
Gan To Kagaku Ryoho. 2013 Jan;40(1):119-23.
The intravenous or subcutaneous route is a useful option for administering opioids when cancer patients with moderate to severe pain are unable to take oral medication. An injectable form of oxycodone is now available, and three patients with cancer-related pain were treated successfully with continuous intravenous or subcutaneous oxycodone. The first case showed transient switching from oral oxycodone to the parenteral form during the active treatment phase, resulting in satisfactory pain management. The second case suggested that oxycodone may have a more favorable analgesic profile in severe neuropathic cancer pain compared with fentanyl. Finally, the third case demonstrated that oxycodone injection is relatively safe for renal-impaired patients.
